Denecimig

Novo Nordisk's once-monthly, every-2-week or once-weekly under-the-skin prophylaxis for hemophilia A with or without inhibitors, under FDA review since September 2025, with the review extended on October 2, 2026 over manufacturing-site fixes and no new decision date, and recommended for EU approval as Frehemgo on September 17, 2026. It works the same way as Hemlibra, standing in for factor VIII, and is given from a single-use prefilled pen.

Factor VIII's job is to hold 2 other clotting proteins, factor IXa and factor X, together long enough for a clot to form. Denecimig is an antibody with 2 arms that grabs one of those proteins with each arm and does that bridging job itself. Because it is not factor VIII, the inhibitor antibodies some people develop against factor VIII replacement do not block it. This is the same approach as emicizumab (Hemlibra); Novo designed denecimig for less frequent dosing, as seldom as once a month.

In the Phase 3 FRONTIER2 trial, injection site reactions were reported by 10% of participants and occurred with 2.6% of injections. No blood clots and no clinical evidence of neutralizing antibodies against denecimig were reported. A US label does not yet exist, so the full warnings are not known; Hemlibra, which works the same way, carries a boxed warning about blood clots and thrombotic microangiopathy when combined with high doses of the bypassing agent aPCC.

Injected under the skin from a single-use prefilled pen, once a month, once every 2 weeks or once a week, according to Novo's European filing. Final US dosing will be set by the FDA label.

Not yet. Denecimig is under FDA review for Hemophilia A; Novo Nordisk has filed an application and a decision is pending. The FDA calendar page tracks the outcome.

There is no date. Novo Nordisk had expected a decision by early autumn 2026, but on October 2, 2026 it announced that the FDA has extended its review because of ongoing remediation at the manufacturing facility after a pre-license inspection, with no new timeline given. The FDA found no deficiencies in the clinical efficacy or safety data, and Novo aims to launch in the US in the first half of 2027 if approved. No PDUFA date was ever disclosed. The FDA calendar page for denecimig is updated when the decision is announced. ^[4]

Both are factor VIIIa mimetics that bridge factor IXa and factor X. Denecimig was built to be given once a month, every 2 weeks or weekly from a prefilled pen; Hemlibra is dosed by weight weekly, every 2 weeks or every 4 weeks after a loading period. They have not been compared in a trial. FRONTIER5 switched people directly from emicizumab to denecimig and reported no new safety signals. ^[3][1]

No. Denecimig is not FDA-approved. Novo Nordisk submitted a biologics license application to the FDA in September 2025 on the strength of its Phase 3 FRONTIER program, and on October 2, 2026 Novo said the FDA had extended its review over manufacturing-facility remediation, with no new decision date and no deficiencies found in the clinical data. In Europe, the CHMP recommended approval on September 17, 2026 under the brand name Frehemgo for adults and children with hemophilia A, with or without inhibitors, and Novo plans to launch in the first European countries in the fourth quarter of 2026. ^[5][4][3]

FRONTIER2 (NCT05053139) included 254 people aged 12 and older with hemophilia A, 12% of them with inhibitors, and compared 26 weeks of monthly or weekly denecimig with each person's prior treatment. Monthly denecimig cut treated bleeds by about 99% versus on-demand treatment and about 43% versus prior factor prophylaxis, while weekly dosing cut them by about 96% and 54%. Between 64% and 95% of people on denecimig had no treated bleeds depending on the arm, injection site reactions were reported by 10% of participants, and no blood clots were reported. Results were published in the New England Journal of Medicine on April 30, 2026. ^[1][2]